Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
|Slideshows|November 13, 2019
Treating Bipolar Depression With Atypical Antipsychotics: Pros, Cons, and Tips
Author(s)Chris Aiken, MD
Depression predominates across the lifespan in patients with bipolar disorder. Here: A discussion about (and beyond) the four FDA-approved drugs to treat symptoms.
Advertisement
Advertisement
Related to this article
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Advertisement
Advertisement
Trending on Psychiatric Times
1
How Best to Manage Treatment-Resistant Depression
2
Antipsychotic Plasma Levels in Schizophrenia: Detecting Nonadherence and Guiding Dose Decisions
3
Choosing an Antidepressant: Art, Science, and Knowing Your Patient
4
Podcast: Using Antipsychotic Plasma Levels to Guide Schizophrenia Treatment With Jonathan M. Meyer, MD
5